leukemia

PLZF-RAR alpha fusion proteins generated from the variant t(11; 17)(q23; q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors.

Treatment concepts of acute promyelocytic leukemia.

A, Typical, hypergranular acute promyelocytic leukemia (APL) exhibiting numerous well-granulated abnormal promyelocytes and multiple cytoplasmic Auer rods.

Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with ATRA: A report by the GIMEMA Group.

Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML).

HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia.

GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.

The favorable-risk group includes acute promyelocytic leukemia with t(15;17) and is the only AML subtype that is associated with a specific therapy (ie, trans-retinoic acid).

Acute promyelocytic leukemia (APL), a M3 type of AML based on French-American-British (FAB) classification, is uniquely sensitive to undergo terminal differentiation by differentiation-inducing agents, such as retinoids (i.

related to the achievement of a milestone for US Food and Drug Administration approval of Trisenox (arsenic trioxide) for first line treatment of acute promyelocytic leukemia, the company said.

Acute promyelocytic leukemia (APL) is the M3 subtype of AML that affects mainly the white blood cells.

Her cause of death was given as asphyxiation, due to a respiratory tract haemorrhage, due to methotrexate [oral chemotherapy drug] toxicity, due to renal failure, due to acute promyelocytic leukemia (APL).

Although acute promyelocytic leukemia (APL) accounts for 12-15% of therapy-related AML (t-AML), these cases typically occur following chemotherapy with topoisomerase II inhibitor and only occasionally following radiation therapy.

There was one case report showing secondary acute promyelocytic leukemia following oxaliplatin plus capecitabine therapy [sup][6] while secondary CML following oxaliplatin was not reported yet.

Vesanoid has been approved by the Mexican government agency, the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), for the treatment of Acute Promyelocytic Leukemia (APL), the M3 subtype of Acute Myelogenous Leukemia (AML), with commercialization anticipated for the fourth quarter of 2016.